Cancer risk in people with epilepsy using valproate-sodium

Acta Neurologica Scandinavica

Volumn 125, Issue 4, 2012, Pages 234-240

  Singh, G ^a,b   Bell, G S ^b,c   Driever, P Hernáiz ^e   Sander, J W ^b,c,d  

^a DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c EPILEPSY SOCIETY   (United Kingdom)

^d STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cancer; Epilepsy; Risk; Valproate sodium

Indexed keywords

VALPROIC ACID;

ADULT; ALCOHOL CONSUMPTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; BREAST CANCER; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RISK; CANCER THERAPY; COLON CANCER; CONTROLLED STUDY; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE TUMOR; SMOKING;

ADULT; CAUSALITY; COMORBIDITY; EPILEPSY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK; VALPROIC ACID; YOUNG ADULT;

EID: 84858293641     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01607.x     Document Type: Article

References (34)

1. Anonymous. Statistics on the risk of developing cancer. Accessed 31/08/2009.
2. Clemmesen J, Fuglsang-Frederiksen V, Plum CM. Are anticonvulsants oncogenic? Lancet 1974;1:705-7.
3. Singh G, Driever PH, Sander JW. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 2005;128:7-17.
4. Adelow C, Ahlbom A, Feychting M, Johnsson F, Schwartzbaum J, Tomson T. Epilepsy as a risk factor for cancer. J Neurol Neurosurg Psychiatry 2006;77:784-6.
5. Driver HE, Mclean AE. Dose-response relationship for phenobarbitone promotion of liver tumours initiated by single dose dimethylnitrosamine. Br J Exp Pathol 1986;67:131-9.
6. Peraino C, Fry RJ, Staffeldt E. Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in the rat by 2-acetylaminofluorene. Cancer Res 1971;31:1506-12.
7. Diwan BA, Henneman JR, Nims RW. Enhancement of N-nitrosodiethylamine-initiated hepatocarcinogenesis by phentoin in male F344/NCr rats at a dose causing maximal induction of CYP2B. Int J Toxicol 2001;20:81-7.
8. Clemmesen J, Hjalgrim-Jensen S. Is phenobarbital carcinogenic? A follow-up of 8078 epileptics. Ecotoxicol Environ Saf 1978;1:457-70.
9. Olsen JH, Boice JD Jr, Jensen JP, Fraumeni JF Jr. Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst 1989;81:803-8.
10. Olsen JH, Schulgen G, Boice JD Jr. et al. Antiepileptic treatment and risk for hepatobiliary cancer and malignant lymphoma. Cancer Res 1995;55:294-7.
11. Shirts SB, Annegers JF, Hauser WA, Kurland LT. Cancer incidence in a cohort of patients with seizure disorders. J Natl Cancer Inst 1986;77:83-7.
12. White SJ, Mclean AE, Howland C. Anticonvulsant drugs and cancer. A cohort study in patients with severe epilepsy. Lancet 1979;2:458-61.
13. Singh G, Fletcher O, Bell GS, Mclean AE, Sander JW. Cancer mortality amongst people with epilepsy: a study of two cohorts with severe and presumed milder epilepsy. Epilepsy Res 2009;83:190-7.
14. Blaheta RA, Michaelis M, Driever PH, Cinatl J Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005;25:383-97.
15. Gottlicher M, Minucci S, Zhu P et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-78.
16. Bouzar AB, Boxus M, Defoiche J et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 2009;144:41-52.
17. Cimino G, Lo-Coco F, Fenu S et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006;66:8903-11.
18. Lawson DH, Sherman V, Hollowell J. The General Practice Research Database. Scientific and Ethical Advisory Group. QJM 1998;91:445-52.
19. Hallas J, Friis S, Bjerrum L et al. Cancer risk in long-term users of valproate: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2009;18:1714-9.
20. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
21. Sander JW, Bell GS. Reducing mortality: an important aim of epilepsy management. J Neurol Neurosurg Psychiatry 2004;75:349-51.
22. Lhatoo SD, Johnson AL, Goodridge DM, Macdonald BK, Sander JW, Shorvon SD. Mortality in epilepsy in the first 11 to 14years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort. Ann Neurol 2001;49:336-44.
23. Lhatoo SD, Sander JW. Cause-specific mortality in epilepsy. Epilepsia 2005;46(Suppl. 11):36-9.
24. Cinatl J Jr, Kotchetkov R, Blaheta R, Driever PH, Vogel JU, Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol 2002;20:97-106.
25. Catalano MG, Fortunati N, Pugliese M et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2005;90:1383-9.
26. Jawed S, Kim B, Ottenhof T, Brown GM, Werstiuk ES, Niles LP. Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. Eur J Pharmacol 2007;560:17-22.
27. Kawagoe R, Kawagoe H, Sano K. Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 2002;26:495-502.
28. Friedmann I, Atmaca A, Chow KU, Jager E, Weidmann E. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer. J Chemother 2006;18:415-20.
29. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000;184:1-16.
30. Tauboll E, Gregoraszczuk EL, Wojtowicz AK, Milewicz T. Effects of levetiracetam and valproate on reproductive endocrine function studied in human ovarian follicular cells. Epilepsia 2009;50:1868-74.
31. Ogbomo H, Michaelis M, Kreuter J, Doerr HW, Cinatl J Jr. Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett 2007;581:1317-22.
32. Fedier A, Dedes KJ, Imesch P, Von Bueren AO, Fink D. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int J Oncol 2007;31:633-41.
33. Dedes KJ, Dedes I, Imesch P, Von Bueren AO, Fink D, Fedier A. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs 2009;20:321-33.
34. Lamminpaa A, Pukkala E, Teppo L, Neuvonen PJ. Cancer incidence among patients using antiepileptic drugs: a long-term follow-up of 28, 000 patients. Eur J Clin Pharmacol 2002;58:137-41.